This test enables doctors to diagnose the condition earlier and less invasively, and to begin personalized treatment. This may include active pharmaceutical or surgical management.

HerResolve has demonstrated exceptional performance in validation studies and is intended to assist healthcare providers in diagnosing endometriosis as part of a comprehensive diagnostic approach. This approach may also include clinical evaluation, imaging (e.g., MRI, ultrasound), and/or laparoscopic surgery +/- histology.

Eligibility for HerResolve Testing

· Females AFAB (assigned female at birth)

· Ages 18 to 49 years old

· Experiencing symptoms suggestive of endometriosis (e.g. dysmenorrhea, chronic pelvic pain, dyspareunia, infertility)

· Patients are not qualified for HerResolve testing if they are pregnant, lactating, no longer menstruating, or undergoing cancer treatment.

At time of blood draw, patient must not be on antibiotics for at least 1 week and/or not be on GnRH hormone therapy for at least 1 month.

HerResolve can only be ordered by doctors and is currently available at select IVF locations nationwide, with plans for expansion to increase patient accessibility.

Robust supportive evidence for HerResolve includes a peer-reviewed clinical validation study published in the Journal of Minimally Invasive Gynecology (JMIG). This study evaluated hundreds of patients in collaboration with clinical sites across the U.S., Europe, and Hong Kong.